|
|
|
May 2007
Axxam and PerkinElmer Sign Exclusive Licensing & R&D Collaboration Agreement for Photina® Technology
Axxam, a science-driven biotechnology company focused on early-stage discovery research and services for the life science industry, and PerkinElmer, a global technology leader in Health Sciences and Photonics, have signed a global licensing agreement whereby PerkinElmer will become the exclusive provider of the Axxam Photina® photoprotein technology to the drug discovery market.
Axxam retains the rights to use the technology for its discovery services to third parties, as assay development, high-throughput screening (HTS) and compound profiling, as well as for any further application of development of this technology. This agreement does not affect current discovery service contracts.
The terms of the agreement also provide for a formal research and development program between Axxam and PerkinElmer to develop additional Photina® GPCR and ion channel cell lines for use in high throughput screening and compound profiling.
The Photina® technology is a luminescent cell-based assay platform optimized for screening important drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels.
April 2007
Axxam & InterMed Discovery Offer Integrated Screening Discovery
Services from Natural Products for Flavor
& Fragrance Industry
Axxam and InterMed Discovery announced a three-year collaboration
to provide complete screening solutions for the identification
of bioactive compounds from natural sources to the flavor and fragrance
industries. Axxam will provide assays and carry out the screening.
InterMed will provide the naturally-derived chemical matter, and
screening samples, as well as deconvolution and scale-up of the
identified compounds.
Together the discovery service providers offer integrated solutions
for the discovery and scale-up of bioactive product candidates
derived from natural sources, such as plants, fungi and microorganisms.
The complementary tools and know-how of both companies will simplify
the discovery process for clients from the food, beverages, flavor
and fragrance industries.
January 2007
Axxam Announces Two Discovery Collaboration
Agreements with Boehringer Ingelheim
Axxam announced that the discovery research and services company
has entered into two drug research collaboration agreements with
Boehringer Ingelheim. The first collaboration agreement aims to
identify and validate therapeutic targets with subsequent assay
development, high-throughput screening (HTS) and lead optimization
through the joint efforts of Axxam and Boehringer Ingelheim researchers.
The second agreement covers the transfer of protein material and
a corresponding specific functional assay for high-throughput screening
(HTS) to Boehringer Ingelheim. Axxam will receive fees as the collaboration
progresses and milestone payments for successful exploitation of
results through development stages. Further financial details of
the agreements are not disclosed.
|
|
|
|
|
|
|
